Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Presentation document (Nov 10, 2025)
[Summary]Consolidated Financial Results for the Six Months Ended September 30, 2025) [Japanese GAAP]
Consolidated Financial Results for Second Quarter (Interim Period) of FY2025 - Supplementary Information
KYORIN Pharma, First Half Ordinary Profit Decreases by 23%, Jul-Sep Ordinary Profit Turns to Loss
KYORIN and Hinge Bio Enter into a Collaboration and License Agreement of HB2198 in Japan for SLE and other diseases
Topline Results from Phase 3 Clinical Study of KRP-R120 for Interstitial Lung Disease
Summary of Consolidated Financial Results(For the first quarter ended June 30, 2025) [Japanese GAAP]
Consolidated Financial Results for First Quarter of FY2025 - Supplementary Information
KYORIN Pharma, Apr-Jun (1Q) Ordinary Profit Increases by 85%, Exceeds First Half Plan
Launch of Beova Tablets in Thailand for Overactive Bladder
Notice of Dividends from Retained Earnings
Notice Regarding Cancellation of Treasury Stock
Announcement of Executive Personnel Changes
Summary of Consolidated Financial Results(For fiscal year ended March 31, 2025) [Japanese GAAP]
Notice Regarding Revision to Annual Dividend Forecast (Special Dividend)
Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (May 12 2025) - Supplementary Information
KYORIN Pharma, 52% Decrease in Ordinary Profit for The Current Fiscal Year, Increased Previous Year's Dividend by 5 yen, Plan to Continue the 57 yen Policy This Fiscal Year as Well
Notice of Upward Revisions to Earnings Forecasts
KYORIN Pharma, Last Fiscal Year Ordinary Profit Revised Upward by 91%
KYORIN and Novartis Enter into a Global License Agreement for KRP-M223